{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:04:23Z","timestamp":1783919063644,"version":"3.55.0"},"reference-count":50,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Systemic mastocytosis (SM) is a clonal mast cell (MC) neoplasm driven by somatically acquired activating mutations in the KIT receptor tyrosine kinase (CD117), resulting in pathological accumulation of morphologically atypical MCs in extracutaneous organs. The KIT D816V substitution is detectable in over 95% of cases by high-sensitivity next-generation sequencing (NGS) or allele-specific PCR. This gain-of-function variant confers ligand-independent receptor autophosphorylation, leading to constitutive activation of downstream signaling cascades that promote MC progenitor survival, clonal expansion, and resistance to apoptosis. Co-occurring somatic mutations in TET2, SRSF2, ASXL1, CBL, and RUNX1, increasingly identified in the context of clonal hematopoiesis of indeterminate potential, are associated with more aggressive phenotypes and independently confer adverse prognostic impact. Results: The 2022 WHO classification delineates indolent forms from advanced-phase SM, aggressive SM, SM with an associated hematologic neoplasm (SM-AHN), and MC leukemia, which produce progressive end-organ damage through both neoplastic tissue infiltration and uncontrolled mediator release. Formal diagnosis requires integration of histological criteria (multifocal bone marrow MC aggregates of \u226515 cells), immunophenotypic aberrancies (CD25, CD2, and\/or CD30 coexpression on MCs by flow cytometry or immunohistochemistry), biochemical markers (baseline serum tryptase \u2265 20 ng\/mL), and molecular confirmation of KIT D816V or equivalent pathogenic KIT mutation. The development of type I KIT inhibitors with selectivity for the D816V-mutant conformation has fundamentally restructured the therapeutic field of advanced SM. Conclusions: This review provides a thorough synthesis of SM pathobiology, WHO-defined diagnostic and classification criteria, validated prognostic tools, and the developing landscape of KIT-directed and combination therapies, with direct translational relevance for specialist practitioners managing this heterogeneous myeloid neoplasm.<\/jats:p>","DOI":"10.3390\/cancers18142205","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:40:09Z","timestamp":1783525209000},"page":"2205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Mastocytosis: Molecular Pathophysiology, WHO Diagnostic Framework, and KIT-Directed Targeted Therapies"],"prefix":"10.3390","volume":"18","author":[{"given":"Caterina","family":"Alati","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bruna","family":"Greve","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-349X","authenticated-orcid":false,"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2684-9269","authenticated-orcid":false,"given":"Erica","family":"Bilardi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Utano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4141","authenticated-orcid":false,"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.jaip.2024.03.010","article-title":"Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?","volume":"12","author":"Akin","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2018.04.002","article-title":"Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence","volume":"38","author":"Hamilton","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_3","first-page":"e22177","article-title":"Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice","volume":"14","author":"Leru","year":"2022","journal-title":"Cureus"},{"key":"ref_4","first-page":"2348","article-title":"Mast cell activation syndromes\u2014Evaluation of current diagnostic criteria and laboratory tools in clinical practice (Review)","volume":"20","author":"Leru","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13054-015-0956-z","article-title":"Critical care management of systemic mastocytosis: When every wasp is a killer bee","volume":"19","year":"2015","journal-title":"Crit. Care"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cilloni, D., Maffeo, B., Savi, A., Danzero, A.C., Bonuomo, V., and Fava, C. (2024). Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202408.2240.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12016-017-8619-2","article-title":"Mastocytosis: From a Molecular Point of View","volume":"54","author":"Komi","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-026-01257-6","article-title":"Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation","volume":"26","author":"Valent","year":"2026","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/cea.70101","article-title":"Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study","volume":"55","author":"Triggiani","year":"2025","journal-title":"Clin. Exp. Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e229967","DOI":"10.1136\/bcr-2019-229967","article-title":"Systemic mastocytosis: Variable manifestations can lead to a challenging diagnostic process","volume":"12","author":"Nallamilli","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lange, M., Hartmann, K., Carter, M.C., Siebenhaar, F., Alvarez-Twose, I., Torrado, I., Brockow, K., Renke, J., Irga-Jaworska, N., and Plata-Nazar, K. (2021). Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052586"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","article-title":"Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Crupi, F., Caroprese, J., and Mannelli, F. (2025). Defining \u201cNormal\u201d basal serum tryptase levels: A context-dependent approach to improve diagnostics in systemic mastocytosis. Front. Allergy, 6.","DOI":"10.3389\/falgy.2025.1592001"},{"key":"ref_15","unstructured":"NCCN (2026, July 01). Clinical Practice Guidelines in Oncology: Systemic Mastocytosis. v.1.2026. Systemic Mastocytosis\u2014Guidelines Detail. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1490."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal","volume":"5","author":"Valent","year":"2021","journal-title":"HemaSphere"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2021046","DOI":"10.4084\/MJHID.2021.046","article-title":"Systemic Mastocytosis: Molecular Landscape and Implications for Treatment","volume":"13","author":"Monaldi","year":"2021","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Cortes","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/bloodadvances.2025017519","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study","volume":"10","author":"Gotlib","year":"2026","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus Placebo in Indolent Systemic Mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2025-2024","article-title":"Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer","volume":"146","author":"Tashi","year":"2025","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-024-00737-8","article-title":"Systemic Mastocytosis: State of the Art","volume":"19","author":"Farmer","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14728214.2023.2221028","article-title":"Systemic mastocytosis: 2023 update on diagnosis and management in adults","volume":"28","author":"Costa","year":"2023","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ACI.0000000000001079","article-title":"New treatments for systemic mastocytosis in 2025","volume":"25","author":"Costanzo","year":"2025","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2023-188904","article-title":"Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial","volume":"142","author":"Tashi","year":"2023","journal-title":"Blood"},{"key":"ref_29","unstructured":"(2026, July 01). Phase 2\/3 Harbor Study of Elenestinib in ISM: A Trial-in-Progress Update of Novel Endpoints and Biomarkers Aimed at Evaluating Disease Modification. Available online: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4162181\/ivan.alvarez-twose.phase.2.3.harbor.study.of.elenestinib.in.ism.a.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica"},{"key":"ref_31","unstructured":"(2026, July 01). A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05186753."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood-2025-80","article-title":"Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis","volume":"146","author":"Rein","year":"2025","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.HS9.0000847064.38588.9b","article-title":"P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults with Advanced Systemic Mastocytosis (APEX): Methods, Baseline Data, and Early Insights","volume":"6","author":"DeAngelo","year":"2022","journal-title":"HemaSphere"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2024-193678","article-title":"Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.18176\/jiaci.1077","article-title":"Tyrosine Kinase Inhibitors for the Treatment of Mast Cell Diseases: Review and Update","volume":"35","author":"Guilarte","year":"2025","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: A magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Veitch, S., and Radia, D.H. (2023). Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14010080"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_42","unstructured":"(2026, July 01). Avapritinib with Decitabine in Patients with SM-AHN, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06327685."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.19245","article-title":"Advanced systemic mastocytosis-Revised classification, new drugs and how we treat","volume":"204","author":"Pardanani","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.5114\/ada.2021.108435","article-title":"Assessing quality of life in patients with mastocytosis: Development of the disease-specific questionnaire","volume":"38","author":"Niedoszytko","year":"2021","journal-title":"Post\u0119py Dermatol. Alergol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/all.12920","article-title":"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis","volume":"71","author":"Safy","year":"2016","journal-title":"Allergy"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:11:36Z","timestamp":1783915896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":50,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142205"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142205","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}